You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rapid, Near-Tranfusion Test for Bacteria in Platelets Units

    SBC: IMMUNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Bacterial contamination of platelets is considered the greatest infectious risk of blood product transfusion today at about in platelet units which is several orders of magnitude greater than that of HIV Bacterial contamination at high levels can lead to severe morbidity or mortality in transfusion recipients The American Association of Blood Banks is ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Selective Inhibitors of NaV as Therapeutics for Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: 108

    PROJECT SUMMARY This program aims to develop a novel non opioid therapeutic for the treatment of pain that targets a subtype of the human voltage gated Na ion channel NaV Preliminary data indicate that SiteOneandapos s lead drug candidates may be more effective than opioids for treating certain types of pain and lack the side effects associated with opioid analgesics which include nausea ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Phosphodiesterase-4B (PDE4B) Inhibitors for Alzheimer's Disease

    SBC: Tetra Discovery Partners, Inc.            Topic: 101

    Under the parent grantTetra Discovery Partners is developing phosphodiesteraseBPDE Ballosteric inhibitors as a treatment for major depressive disorderUniquelythe Tetra drug will address inflammation as a contributor to depressionThis is a new mechanism of action for an antidepressant drug which should prove complimentary to current therapeuticsThe company estimates thatof patients with depression ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: ADECTO PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Dual-view endoscopic probe

    SBC: Omniscient Imaging, Inc.            Topic: 102

    DESCRIPTION provided by applicant Colon cancer is a leading cause of cancer death in the United States and overseas Colonoscopy is the preferred screening method at an estimated annual cost of over $ billion in the US Unfortunately many lesions are missed because pre cancerous growths remain hidden from view behind folds and flexures of the colon Current methods of increasing the field of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development

    SBC: NUVOX PHARMA, L.L.C.            Topic: 394

    DESCRIPTION provided by applicant Pancreatic ductal adenocarcinoma PDAC is a deadly form of cancer and patient survival depends upon the stage of diagnosis While overall survival at diagnosis is only about months of patients with stage I disease survive years The best currently available diagnostic test which is routinely performed in patients at high risk for PDAC is endoscop ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Nanoparticle Delivery System for Ewing Sarcoma Treatment

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    DESCRIPTION provided by applicant This Phase I STTR project seeks to demonstrate proof of principle that novel targetable nanoparticles can delivery therapeutic substances to human tumor cells and reduce tumor burden in metastatic cancer The concept for these nanoparticles is based on the polymerized liposome nanoparticle PLN that displays functional antibodies that target tumor cell surfac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain

    SBC: On Target Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government